Special Issue

Development of Bone Anabolic Agents and Scaffolds for Improved Fracture Healing

Message from the Guest Editor

Fracture healing is a complex biological process, triggered by trauma injury or in association with osteoporosis. Depending on its severity, location and patient bone quality, delayed, impaired or nonunion fracture healing can occur. Addressing these situations is extremely critical as they lead to reduced mobility, excessive pain, bone infections and bone deformities. Therefore, the development of bone anabolic agents and tissue scaffolds to improve fracture healing is an unmet medical need. In this issue, we are looking for research articles using novel bone anabolic agents and tissue scaffolds for fracture healing in relevant animal models. Human case studies related to novel approaches for nonunion fracture healing are also a topic of interest for this Special Issue. Current research indicates that probiotics and gut microbiomes could play a beneficial role in fracture healing. To move forward in this direction, articles focusing on the use of probiotics or the gut–fracture healing axis will be given special emphasis for this issue.

Guest Editor

Dr. Subhashis Pal

Division of Medical Research, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu 603203, India

Deadline for manuscript submissions

closed (31 July 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/179895

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).